NASDAQ:CING Cingulate (CING) Stock Price, News & Analysis $5.26 -0.12 (-2.25%) As of 02:00 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Cingulate Stock (NASDAQ:CING) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cingulate alerts:Sign Up Key Stats Today's Range$5.23▼$5.6550-Day Range$3.60▼$5.8952-Week Range$3.16▼$11.89Volume132,237 shsAverage Volume511,725 shsMarket Capitalization$70.84 millionP/E RatioN/ADividend YieldN/APrice Target$27.33Consensus RatingModerate Buy Company Overview Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas. Read More Cingulate Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreCING MarketRank™: Cingulate scored higher than 56% of companies evaluated by MarketBeat, and ranked 347th out of 850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingCingulate has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCingulate has a consensus price target of $27.33, representing about 411.4% upside from its current price of $5.35.Amount of Analyst CoverageCingulate has only been the subject of 4 research reports in the past 90 days.Read more about Cingulate's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cingulate are expected to grow in the coming year, from ($2.40) to ($1.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cingulate is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cingulate is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCingulate has a P/B Ratio of 17.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cingulate's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.81% of the float of Cingulate has been sold short.Short Interest Ratio / Days to CoverCingulate has a short interest ratio ("days to cover") of 1.91, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cingulate has recently decreased by 10.10%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCingulate does not currently pay a dividend.Dividend GrowthCingulate does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Cingulate this week, compared to 4 articles on an average week.Search InterestOnly 9 people have searched for CING on MarketBeat in the last 30 days. This is a decrease of -59% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cingulate insiders have not sold or bought any company stock.Percentage Held by Insiders5.30% of the stock of Cingulate is held by insiders.Percentage Held by Institutions41.31% of the stock of Cingulate is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cingulate's insider trading history. Receive CING Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CING Stock News HeadlinesCingulate Inc. (NASDAQ: CING) Added to Russell 3000E®July 2, 2026 | globenewswire.comFutures fever - Apex Trader Funding & all-access ft. Cingulate (NASDAQ: CING)June 29, 2026 | msn.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.July 6 at 1:00 AM | Profits Run (Ad)Innovation is the Best Medicine: How CEO Shane Schaffer and Cingulate Developed “Precision Timed Release,” a New Drug Delivery Platform for ADHDJune 25, 2026 | thestreet.comCingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHDJune 23, 2026 | stockhouse.comCingulate Gains Key U.S. Patent for Lead ADHD DrugJune 16, 2026 | tipranks.comCingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301June 16, 2026 | globenewswire.comCingulate (NASDAQ:CING) Director Purchases $490,271.04 in StockJune 9, 2026 | insidertrades.comSee More Headlines CING Stock Analysis - Frequently Asked Questions How have CING shares performed this year? Cingulate's stock was trading at $4.34 at the beginning of 2026. Since then, CING shares have increased by 23.2% and is now trading at $5.3450. How were Cingulate's earnings last quarter? Cingulate Inc. (NASDAQ:CING) posted its quarterly earnings data on Thursday, May, 14th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by $0.42. When did Cingulate's stock split? Cingulate shares reverse split on Thursday, November 30th 2023.The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Cingulate IPO? Cingulate (CING) raised $29 million in an initial public offering (IPO) on Wednesday, December 8th 2021. The company issued 4,166,666 shares at a price of $6.00-$8.00 per share. How do I buy shares of Cingulate? Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cingulate own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cingulate investors own include NVIDIA (NVDA), Windtree Therapeutics (WINT), AMC Entertainment (AMC), Sonnet BioTherapeutics (SONN), ARMOUR Residential REIT (ARR), BioCardia (BCDA) and Company Calendar Last Earnings5/14/2026Today7/06/2026Next Earnings (Estimated)8/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 CING's financial health is in the Yellow zone, according to TradeSmith. CING has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CING CIK1862150 Webwww.cingulate.com Phone913-942-2300FaxN/AEmployees20Year Founded2012Price Target and Rating Average Price Target for Cingulate$27.33 High Price Target$52.00 Low Price Target$10.00 Potential Upside/Downside+421.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($4.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.45 million Net MarginsN/A Pretax MarginN/A Return on Equity-365.15% Return on Assets-158.55% Debt Debt-to-Equity RatioN/A Current Ratio2.55 Quick Ratio2.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.31 per share Price / Book16.92Miscellaneous Outstanding Shares13,470,000Free Float12,755,000Market Cap$70.66 million OptionableNot Optionable Beta-0.91 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:CING) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersAre you leaving Social Security money on the table?Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....Money Pickle | SponsoredYou must do this before the OpenAI IPOOpenAI - the company behind ChatGPT - has begun filing confidential paperwork for what could be the largest IP...InvestorPlace | SponsoredJ.P. Morgan is betting on this coinWhile crypto investors panic-sell amid some of the most extreme fear levels since the 2022 bear market… J.P. M...Crypto 101 Media | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredThe Midterm Trap That Could Ruin Your 401(k)For investors within 5 to 10 years of retirement, midterm election volatility isn't a distant concern - it's a...American Hartford Gold | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | Sponsored“By July 30, Elon Musk’s Prophecy Will Fulfill Itself”Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...Brownstone Research | SponsoredPosition Before the Panic StartsWashington has been valuing America's gold reserves at $42.22 an ounce - a 1973-era figure - while gold trades...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
